A.R.T. Advisors LLC acquired a new position in MEDNAX Inc (NYSE:MD) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 41,100 shares of the company’s stock, valued at approximately $2,286,000.
Other large investors have also recently made changes to their positions in the company. MetLife Investment Advisors LLC bought a new position in MEDNAX in the fourth quarter worth approximately $3,167,000. American International Group Inc. lifted its holdings in MEDNAX by 1.2% during the fourth quarter. American International Group Inc. now owns 197,889 shares of the company’s stock worth $10,575,000 after buying an additional 2,306 shares during the period. FDx Advisors Inc. lifted its holdings in MEDNAX by 10.5% during the fourth quarter. FDx Advisors Inc. now owns 15,304 shares of the company’s stock worth $818,000 after buying an additional 1,450 shares during the period. Paloma Partners Management Co lifted its holdings in MEDNAX by 239.9% during the fourth quarter. Paloma Partners Management Co now owns 128,825 shares of the company’s stock worth $6,884,000 after buying an additional 90,925 shares during the period. Finally, GHP Investment Advisors Inc. lifted its holdings in MEDNAX by 13.8% during the fourth quarter. GHP Investment Advisors Inc. now owns 7,735 shares of the company’s stock worth $413,000 after buying an additional 940 shares during the period. 97.39% of the stock is currently owned by institutional investors.
MD has been the subject of a number of analyst reports. TheStreet upgraded MEDNAX from a “c+” rating to a “b” rating in a report on Monday, March 12th. Zacks Investment Research upgraded MEDNAX from a “sell” rating to a “hold” rating in a report on Saturday, May 5th. Jefferies Financial Group set a $58.00 target price on MEDNAX and gave the stock a “hold” rating in a report on Thursday, March 15th. Credit Suisse Group lowered their target price on MEDNAX to $57.00 and set a “neutral” rating for the company in a report on Monday, May 7th. Finally, Citigroup lowered their target price on MEDNAX from $57.00 to $50.00 and set a “neutral” rating for the company in a report on Friday, May 4th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and three have assigned a buy rating to the company’s stock. MEDNAX has an average rating of “Hold” and a consensus price target of $55.92.
Shares of MD opened at $44.35 on Monday. MEDNAX Inc has a 12 month low of $40.56 and a 12 month high of $63.04. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.63. The firm has a market cap of $4.19 billion, a PE ratio of 14.08, a price-to-earnings-growth ratio of 1.13 and a beta of 0.24.
MEDNAX (NYSE:MD) last issued its quarterly earnings data on Monday, April 30th. The company reported $0.89 EPS for the quarter, beating the consensus estimate of $0.82 by $0.07. MEDNAX had a return on equity of 10.13% and a net margin of 9.34%. The firm had revenue of $901.90 million during the quarter, compared to analyst estimates of $903.75 million. During the same quarter in the prior year, the business posted $0.75 EPS. The business’s revenue for the quarter was up 7.9% compared to the same quarter last year. analysts forecast that MEDNAX Inc will post 3.94 earnings per share for the current year.
In related news, insider David A. Clark sold 11,607 shares of the firm’s stock in a transaction on Friday, June 1st. The stock was sold at an average price of $45.15, for a total value of $524,056.05. Following the completion of the transaction, the insider now owns 32,845 shares in the company, valued at approximately $1,482,951.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John C. Pepia sold 3,000 shares of the firm’s stock in a transaction on Tuesday, May 22nd. The stock was sold at an average price of $46.43, for a total value of $139,290.00. Following the completion of the transaction, the insider now owns 39,716 shares of the company’s stock, valued at approximately $1,844,013.88. The disclosure for this sale can be found here. In the last quarter, insiders have sold 75,251 shares of company stock valued at $3,462,384. Company insiders own 2.40% of the company’s stock.
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.